Actavis Completes Forest Laboratories Acquisition
Creates an Innovative New Model in Specialty Pharmaceuticals Leadership – – $15.0 Billion Anticipated Pro Forma Combined Revenue – – Establishes Blockbuster Franchises in CNS, Gastroenterology, Women’s Health, Urology and Cardiovascular Therapeutic Categories – – Expands Development-Focused Brand and Generic Pipeline – DUBLIN, July 1, 2014 /PRNewswire/ — Actavis plc (NYSE: ACT) today announced that […]